Veeva CRM and Veeva OpenData Help the Life Sciences Industry Meet Compliance Requirements in Ohio

(NYSE: VEEV) today announced new capabilities in Veeva
and licensing data in Veeva
to help life sciences organizations meet government
regulations in Ohio.

Ohio law requires that all healthcare organizations (HCOs) have Terminal
Distributor of Dangerous Drugs (TDDD) licenses to distribute the drugs
that healthcare professionals (HCPs) are prescribing. Provisions were
added to the law this year to oversee the interactions between
pharmaceutical companies and HCOs and the distribution of prescribed

Veeva CRM can now validate that an HCP is at an HCO with an Ohio TDDD
license number before a field representative provides a product or
sample. Together with Veeva OpenData, licensing data flows seamlessly
into Veeva CRM so representatives can ensure pharmacies, hospitals, and
medical practices are properly licensed at the point of distribution.

“Veeva is helping the industry adapt faster to new and changing
regulations,” said Paul Shawah, senior vice president of commercial
strategy at Veeva. “Veeva CRM and Veeva OpenData bring together license
data with CRM so companies can address Ohio TDDD and deliver products to
prescribers without interruption.”

HCOs must have a valid license for the specific category of drug they
want to sample or prescribe. This creates additional complexity for
pharmaceutical companies to ensure prescribers are affiliated with
licensed organizations before they engage with an HCP.

Veeva CRM helps sales representatives quickly confirm affiliations
between HCPs and HCOs and verify an organization has an Ohio TDDD
license. With Veeva OpenData, complete and accurate HCP, HCO, and
affiliation data is automatically cross-referenced and validated in
Veeva CRM.

Ohio TDDD is the latest example of Veeva CRM continuing to evolve and
help the industry keep pace with changing regulations as they take
effect. Veeva enables life sciences companies to adapt quickly to
compliance requirements faster and easier so they can engage compliantly
with HCPs without disruption.

To learn more about how Veeva enables customers to maintain compliance
with the Ohio TDDD law, visit:

Additional Information

For more information on Veeva CRM, visit:

Connect with Veeva on LinkedIn:

Follow @veevasystems on Twitter:

Like Veeva on Facebook:

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 600 customers, ranging from the
world’s largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit

Forward-looking Statements

This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended October 31, 2017. This is available on the
company’s website at
under the Investors section and on the SEC’s website at
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to


Veeva Systems
Roger Villareal, 925-264-8885
Lisa Barbadora, 610-420-3413